A family of oligonucleotides and phosphorothioate oligonucleotide analogues was synthesized with a cholesteryl group tethered at the 3'-terminal internucleoside link. This modification, introduced to enhance interaction of the polyanions with cell membranes, significantly increases the antiviral activity of the oligomers, as judged by inhibition of syncytia formation and expression of viral proteins p17, p24, and reverse transcriptase for human immunodeficiency virus 1 in Molt-3 cells. In the most favorable case, with a 20-mer cholesteryl-phosphorothioate derivative, complete inhibition by all assays was obtained with an oligomer concentration of 0.2 jIM. Even decamers were active, and some antiviral activity was observed for a heptanucleotide cholesteryl-phosphorothioate derivative, which binds very poorly to complementary oligonucleotides. These facts, and the finding that the activity of the phosphorothioate decamers does not correlate with a specific sequence., suggests that a mechanism other than "antisense inhibition" may be operative in these systems.
unmodified oligonucleotides (11, 12) and a polylysine conjugate (13) , have been reported to inhibit viral replication in cell culture. The viruses studied in this context include Rous sarcoma virus (1) , simian virus (5) , vesicular stomatitis virus (6, 13) , human immunodeficiency virus (HIV) (8) (9) (10) (11) (12) , herpes simplex virus (7) , and influenza virus (14) .
The concept underlying this work is that an oligonucleotide complementary to a unique segment of a viral genome, or an RNA derived from it, may selectively disrupt processes dependent on that segment by hybridization. This rationale is supported by a variety of experiments with cell-free systems and with cells to which "antisense" polynucleotides have been inserted by microinjection or transfection (15, 16) . However, the actual mechanisms by which oligonucleotides and their analogues function as inhibitors in cell cultures are still far from clear. Even homooligonucleotides (9, 10) have been found to exhibit activity in some antiviral assays. Little is known about the interaction of the oligomers with cell membranes or the locus of their reactions within cells. It seems likely that nonionic oligomers, such as the methylphosphonate analogues, diffuse passively through cell membranes. Some evidence suggests an active transport mechanism for unmodified oligonucleotides (17) .
We describe here the synthesis, physical properties, and activity as inhibitors of HIV replication in cell culture of a family of oligonucleotides with a modification designed to anchor the oligomer, at least transiently, at the cell membrane. Cholesterol was selected as the anchor since it -is highly hydrophobic and membranes of HIV and'HIVinfected cells are rich in this steroid (18) .
MATERIALS AND METHODS
Synthesis of Oligomers. Oligonucleotides with cholesteryl groups covalently joined at the 3'-terminal internucleoside phosphorus were synthesized on commercial controlled pore glass (CPG) supports. A support-bound dinucleoside hydrogen phosphonate derivative (19) was first prepared manually; then a cholesteryl group was tethered to the internucleoside phosphorus by oxidative phosphoramidation (20) with carbon tetrachloride and cholesteryloxycarbonylaminoethylamine (Scheme I; R is a nucleoside linked at the 3' 0; R' is a support-bound nucleoside linked at the 5' 0). (2 g ) in dichloromethane (6 ml) was added dropwise to a solution of ethylenediamine (2.5 ml) in dichloromethane (6 ml) and pyridine (6 ml ofDMT-ibG) was placed in a Glenco gas-tight syringe (10 ml) equipped with a plug of glass wool at the inlet. Reactions and washings were carried out by drawing in and ejecting the desired solutions. Thus, the dimethoxytrityl group was removed with dichloroacetic acid (2.5% in dichloromethane), the support was washed repeatedly with acetonitrile/pyridine (4:1), coupling was effected by drawing in together DMT-ibG-hydrogen phosphonate (80 mg; 0.1 mmol; in 1.2 ml of acetonitrile/pyridine) and trimethylacetyl chloride (65 szl; 0.5 mmol; in 1.2 ml of acetonitrile/pyridine) (2 min), and the support was washed well with acetonitrile/pyridine. A solution of cholesteryloxycarbonylaminoethylamine (250 mg; 0.5 mmol) in carbon tetrachloride (5 ml) and pyridine (2 ml) was then drawn into the syringe and after 0.5 hr the solution was ejected and the solid was washed well with acetonitrile. Appropriate portions were then transferred to a cartridge for extension by machine synthesis or to a syringe for manual synthesis.
Characterization Procedures. High-performance liquid chromatography (HPLC) was carried out with a C-18 reversed-phase column (5-pm Hypersil ODS; 100 x 2.1 mm) on a Hewlett-Packard 1090 chromatograph using aqueous 0.1 M triethylammonium acetate (pH 7.3) and an acetonitrile gradient (1%/min; flow rate, 0.5 ml/min). Brinkmann silica gel plates (0.25 mm) with fluorescent indicator were used for TLC; they were developed with n-propyl alcohol/ammonium hydroxide/water (55:10:35; vol/vol (8) and HIV-1 p24 antigen expression and reverse transcriptase assays (22, 23) were carried out as described.
RESULTS
The modified oligomers and related parent oligonucleotides synthesized for this study are listed in Table 1 . These compounds were characterized by HPLC, TLC, PAGE, thermal dissociation curves for hybrids formed with complementary strands (Table 1) , and UV and NMR spectroscopy. No separation of stereoisomeric phosphoramidates could be achieved; consequently, the cholesteryl derivatives represent in each case a mixture of R and S stereoisomers at phosphorus. The 31P NMR spectra exhibited the expected peaks near -0.8, +10.5, and +56 for the phosphodiester, phosphoramidate, and phosphorothioate functional groups, respectively (Table 1) . A proton NMR spectrum of compound 2 showed the presence of the cholesteryl fragment. In addition, the hydrophobic nature of the cholesteryl-modified oligonucleotides was clearly revealed by the HPLC data (Table 1) . For example, the elution times for samples analyzed by a reversed-phase C-18 column increased from 12 to 46 to 61 min for compounds 1 (parent), 2 (one cholesteryl), and 4 (two cholesteryls), respectively. Susceptibility to nuclease degradation was examined with compound 2. In the presence of spleen phosphodiesterase and alkaline phosphatase, compound 2 was completely hydrolyzed to the expected IINo break in the A260 vs. t curve was observed.
ttThe complement for compound 15 was poly(dA).
Proc. Natl. Acad. Sci. USA 86 (1989) nucleosides (dl in place of dA) and a fragment corresponding to the terminal d(G*G) [*, the lipophilic phosphoramidate link O=P-NH(CH2)2NHCO2 cholesteryl].
To assess the effect of the lipophilic side chain on hybridization, the dissociation of complexes formed from equimolar quantities of modified and unmodified complementary oligodeoxyribonucleotides was followed by changes in absorbance at 260 nm as a function of temperature. Melting temperature (tm) curves typical for oligonucleotide duplexes were obtained. The data in Table 1 show that introduction ofa single cholesteryl fragment at a terminal internucleoside position has only a minor effect on the stability of the hybrid duplex as measured by tm values (compare compound 1 with 2, 6 with 7, and 8 with 9), but that cholesteryl substituents at both termini appreciably destabilize hybridization (compare 20-mer compound 4, tm 52TC, with compounds 2 and 1, tm 60°().
Inhibition of HIV-1 Replication. The parent oligonucleotide, compound 1, is complementary to the splice acceptor site at nucleotides 5349-5368 in HIV (12) and has been reported to inhibit replication of this virus in Molt-3 cells (11, 12) . The target compounds specified in Table 1 are structural variations of this basic sequence. They were designed to provide information on the anti-HIV properties of cholesteryl-conjugated oligonucleotides-specifically, with respect to changes in the number of cholesteryl substituents, the nature of the backbone, the length of the oligomers, and the sequence.
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in Tables 2 and 3 . There is some scatter in the data obtained from the different assay procedures; however, the patterns from the different tests are the same and the overall agreement is good. For convenience, the results are discussed here in terms of ID50 values for inhibition of syncytia [concentration of an oligomer (ug/ml) that reduces syncytia formation by 50%]. The LD50 value [concentration of oligomer (,ug/ml) that kills 50% ofthe cell population] was >100 for each ofthe compounds listed in Tables 2 and 3 .
Several conclusions may be drawn from these data. (i) The activity of the parent oligonucleotide, compound 1, is low (ID50> 100), in agreement with the previous report (12) . ( 20 -mers, the highest activity was found with a phosphorothioate 20-mer bearing one cholesteryl group (compound 7). Expression of viral proteins p17, p24, and reverse transcriptase and formation of syncytia were all completely inhibited by this compound at a concentration of -0.2 ,uM (1.5 ,ug/ml). Although the shorter oligomers in this family were less active, the relative impact of the cholesteryl modification was greater, since the unmodified parent phosphorothioates in the decamer range and below exhibit little antiviral activity.
The unusual activity of the cholesteryl-conjugated oligonucleotides makes such amphiphilic oligomers promising targets for further study as potential therapeutic agents in the treatment of AIDS and related viral diseases. In addition, these findings open interesting questions concerning the locus ofreaction and the mechanism by which the cholesteryl derivatives inhibit HIV in this cellular system. More data are needed to answer these questions. However, the fact that very short cholesteryl-phosphorothioate derivatives (e.g., heptamer 14), which bind poorly to complementary strands, exhibit appreciable activity and the observation that the activity of the decamers is not dependent on sequence point toward some mechanism other than "antisense inhibition," at least in the case of the shorter oligomers.
